{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:06:47Z","timestamp":1787170007219,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["5R01CA227156-02"],"award-info":[{"award-number":["5R01CA227156-02"]}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008222","name":"Ben and Catherine Ivy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008222","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    KRAS mutations are prevalent in brain metastases (BM) from non-small cell lung cancer (NSCLC). The activity of KRAS-G12C selective, brain-penetrant small molecule inhibitor adagrasib was recently demonstrated in preclinical models of BM and patients with BM carrying KRAS-G12C, leading to a clinical trial investigating this therapeutic approach. However, co-existing genomic drivers such as homozygous deletion of\n                    <jats:italic>CDKN2A\/B<\/jats:italic>\n                    may impact the utility of adagrasib. We therefore explored the combination therapy employing adagrasib and abemaciclib, a brain-penetrant CDK4\/6 inhibitor, in NSCLC BM models driven by KRAS-G12C and\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    loss. In both adagrasib-resistant SW1573 cells and adagrasib-responsive H2122 cells, combination of adagrasib and abemaciclib was slightly synergistic in inhibiting cell viability in vitro through targeting the KRAS-ERK and CDK4\/6-Rb signaling pathways. Combination treatment was necessary to activate caspase 3\/7-mediated apoptosis in SW1573 cells, while adagrasib alone and in combination comparably elicited apoptosis in H2122 cells. In vivo, combination treatment with adagrasib (75\u00a0mg\/kg) twice daily and abemaciclib (50\u00a0mg\/kg) daily was associated with body weight loss (about 10%) in mice bearing orthotopic BM derived with SW1573 or H2122 cells, requiring 50% dose reduction of adagrasib in some animals. Notably, combination treatment, but neither monotherapy, extended animal survival in the SW1573 model. On the other hand, adagrasib monotherapy and combination were similarly effective at prolonging survival, while abemaciclib monotherapy was ineffective in the H2122 model. Pharmacokinetic studies confirmed brain-penetrant properties of both agents and revealed drug-drug interactions as abemaciclib exposures in the plasma and brains were increased by the presence of adagrasib. Immunohistochemistry demonstrated on-target pharmacodynamic effects of both agents in BM in mice. Our work thus supports that the combination treatment of adagrasib and abemaciclib can offer a therapeutic strategy in NSCLC BM genomically characterized by KRAS-G12C and CDKN2A loss.\n                  <\/jats:p>","DOI":"10.1186\/s40478-025-01993-2","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:01:54Z","timestamp":1746169314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A"],"prefix":"10.1186","volume":"13","author":[{"given":"Christian","family":"Migliarese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinon","family":"Sadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Torrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Turna Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naema","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Yamazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuu","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Ijad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rahbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Saechao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8225-241X","authenticated-orcid":false,"given":"Hiroaki","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"1","key":"1993_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L et al (2020) The KRAS(G12C) inhibitor mrtx849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov 10(1):54\u201371","journal-title":"Cancer Discov"},{"issue":"2","key":"1993_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000024","volume":"1","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, Schur S, Fureder LM et al (2016) Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open 1(2):e000024","journal-title":"ESMO Open"},{"issue":"1","key":"1993_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14(1):48\u201354","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1993_CR4","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1993_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ctrv.2013.10.001","volume":"40","author":"SL Wood","year":"2014","unstructured":"Wood SL, Pernemalm M, Crosbie PA, Whetton AD (2014) The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev 40(4):558\u2013566","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"1993_CR6","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","volume":"28","author":"JK Sabari","year":"2022","unstructured":"Sabari JK, Velcheti V, Shimizu K et al (2022) Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with krasg12c-mutant non-small cell lung cancer. Clin Cancer Res 28(15):3318\u20133328","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1993_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2014.25","volume":"11","author":"TK Owonikoko","year":"2014","unstructured":"Owonikoko TK, Arbiser J, Zelnak A et al (2014) Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol 11(4):203\u2013222","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1993_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JOP.19.00357","volume":"15","author":"V Ernani","year":"2019","unstructured":"Ernani V, Stinchcombe TE (2019) Management of brain metastases in non-small-cell lung cancer. J Oncol Pract 15(11):563\u2013570","journal-title":"J Oncol Pract"},{"issue":"Suppl 3","key":"1993_CR9","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.21037\/tlcr.2019.05.15","volume":"8","author":"M Nishino","year":"2019","unstructured":"Nishino M, Soejima K, Mitsudomi T (2019) Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res 8(Suppl 3):S298\u2013S307","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"1993_CR10","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.3747\/co.20.1481","volume":"20","author":"A Ali","year":"2013","unstructured":"Ali A, Goffin JR, Arnold A, Ellis PM (2013) Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 20(4):e300-306","journal-title":"Curr Oncol"},{"issue":"11","key":"1993_CR11","first-page":"5797","volume":"35","author":"WC Dempke","year":"2015","unstructured":"Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A (2015) Brain metastases in NSCLC - are TKIs changing the treatment strategy? Anticancer Res 35(11):5797\u20135806","journal-title":"Anticancer Res"},{"issue":"4","key":"1993_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419\u2013425","journal-title":"J Clin Oncol"},{"issue":"14","key":"1993_CR13","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL (2020) The Frequency of Ras mutations in cancer. Cancer Res 80(14):2969\u20132974","journal-title":"Cancer Res"},{"issue":"7","key":"1993_CR14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs GA, Der CJ, Rossman KL (2016) RAS isoforms and mutations in cancer at a glance. J Cell Sci 129(7):1287\u20131292","journal-title":"J Cell Sci"},{"key":"1993_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00621","volume":"7","author":"G Lamberti","year":"2023","unstructured":"Lamberti G, Aizer A, Ricciuti B et al (2023) Incidence of brain metastases and preliminary evidence of intracranial activity with sotorasib in patients with KRAS(G12C)-mutant non-small-cell lung cancer. JCO Precis Oncol 7:e2200621","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"1993_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.cllc.2023.05.002","volume":"24","author":"J Isaksson","year":"2023","unstructured":"Isaksson J, Berglund A, Louie K et al (2023) KRAS G12C mutant non-small cell lung cancer linked to female sex and high risk of CNS metastasis: population-based demographics and survival data from the national Swedish lung cancer registry. Clin Lung Cancer 24(6):507\u2013518","journal-title":"Clin Lung Cancer"},{"issue":"25","key":"1993_CR17","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II et al (2021) Acquired resistance to KRAS(G12C) Inhibition in cancer. N Engl J Med 384(25):2382\u20132393","journal-title":"N Engl J Med"},{"issue":"4","key":"1993_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","volume":"52","author":"DJH Shih","year":"2020","unstructured":"Shih DJH, Nayyar N, Bihun I et al (2020) Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet 52(4):371\u2013377","journal-title":"Nat Genet"},{"issue":"11","key":"1993_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel S, DeCristo MJ, McAllister SS, Zhao JJ (2018) CDK4\/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol 28(11):911\u2013925","journal-title":"Trends Cell Biol"},{"issue":"7","key":"1993_CR20","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao MV, Araujo HA, Lamberti G et al (2023) Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov 13(7):1556\u20131571","journal-title":"Cancer Discov"},{"issue":"5","key":"1993_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s43018-021-00198-5","volume":"2","author":"PK Brastianos","year":"2021","unstructured":"Brastianos PK, Kim AE, Wang N et al (2021) Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer 2(5):498\u2013502","journal-title":"Nat Cancer"},{"issue":"6","key":"1993_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","volume":"32","author":"X Gong","year":"2017","unstructured":"Gong X, Litchfield LM, Webster Y et al (2017) Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. Cancer Cell 32(6):761-776.e6","journal-title":"Cancer Cell"},{"issue":"9","key":"1993_CR23","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1124\/dmd.114.062745","volume":"43","author":"TJ Raub","year":"2015","unstructured":"Raub TJ, Wishart GN, Kulanthaivel P et al (2015) Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos 43(9):1360\u20131371","journal-title":"Drug Metab Dispos"},{"issue":"18","key":"1993_CR24","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D et al (2016) Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32(18):2866\u20132868","journal-title":"Bioinformatics"},{"issue":"20","key":"1993_CR25","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","volume":"26","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Sahebjam S, Le Rhun E et al (2020) A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 26(20):5310\u20135319","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1993_CR26","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-24-0562","volume":"30","author":"AM Nasser","year":"2024","unstructured":"Nasser AM, Melamed L, Wetzel EA et al (2024) CDKN2A\/B homozygous deletion sensitizes IDH-mutant glioma to CDK4\/6 inhibition. Clin Cancer Res 30(14):2996\u20133005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1993_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin CM, Waters AM, Klomp JE et al (2023) Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res 83(1):141\u2013157","journal-title":"Cancer Res"},{"issue":"3","key":"1993_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/15384047.2019.1685291","volume":"21","author":"D Frisone","year":"2020","unstructured":"Frisone D, Charrier M, Clement S et al (2020) Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss. Cancer Biol Ther 21(3):197\u2013202","journal-title":"Cancer Biol Ther"},{"key":"1993_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00124","volume":"3","author":"T Al Baghdadi","year":"2019","unstructured":"Al Baghdadi T, Halabi S, Garrett-Mayer E et al (2019) Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 3:1\u20138","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1993_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25\u201335","journal-title":"Lancet Oncol"},{"key":"1993_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ejca.2021.02.021","volume":"148","author":"L Mao","year":"2021","unstructured":"Mao L, Dai J, Cao Y et al (2021) Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer 148:297\u2013306","journal-title":"Eur J Cancer"},{"key":"1993_CR32","first-page":"1","volume":"3","author":"J Peguero","year":"2019","unstructured":"Peguero J, Sohal DPS, O\u2019Neil BH et al (2019) Tissue\/site-agnostic study of ribociclib for tumors with cyclin D-CDK4\/6 pathway genomic alterations: a phase II, open-label. Single-Arm Basket Study JCO Precis Oncol 3:1\u201310","journal-title":"Single-Arm Basket Study JCO Precis Oncol"},{"issue":"8","key":"1993_CR33","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U et al (2016) Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76(8):2301\u20132313","journal-title":"Cancer Res"},{"key":"1993_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105954","volume":"178","author":"A Martinez-Chavez","year":"2022","unstructured":"Martinez-Chavez A, Loos NHC, Lebre MC et al (2022) ABCB1 and ABCG2 limit brain penetration and together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. Pharmacol Res 178:105954","journal-title":"Pharmacol Res"},{"issue":"2","key":"1993_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann T, Sers C, Der CJ, Papke B (2025) KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer 11(2):91\u2013116","journal-title":"Trends Cancer"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-01993-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-01993-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-01993-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:02:36Z","timestamp":1764014556000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-01993-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1993"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-01993-2","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The Funding information was missing and should have read \u2018C.T. was supported by NIH funding (2T32HG010464-06) for the Mass General Brigham T32 Training Program\u2019.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PKB has consulted for Atavistik, CraniUS, Eli Lilly, Genentech, InCephalo, Kazia, ACI, Angiochem, Axiom, Dantari, Elevatebio, Merck, MPM, Pfizer, Sintetica, SK Life Sciences, Tesaro, and Voyager, serves on the scientific advisory board for CraniUS and Kazia, and has received grant funding (to MGH) from Merck, Eli Lilly, Kinnate and Mirati.\u00a0F.T.D. was supported by the 2219 International Postdoctoral Research Fellowship Program from the Scientific and Technological Research Council of Turkey (T\u00dcB\u0130TAK), Ankara, Turkey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}